Table 2.
Multivariate cox regression analysis indicating significant risk factors for progression-free survival in patients treated with combination chemotherapy and immunotherapy
| Characteristics | Chemotherapy plus ICI | Chemotherapy alone | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| CRP (Elevated vs. Normal) | 1.84 | 1.13–3.00 | 0.014 | 1.89 | 1.06–3.36 | 0.031 |
| Age (≥65 vs. < 65 years) | 0.97 | 0.61–1.54 | 0.891 | |||
| Sex (Male vs. Female) | 1.15 | 0.46–2.88 | 0.761 | |||
| Smoke (Current/Former vs. Never) | 1.28 | 0.51–3.19 | 0.596 | |||
| ECOG score (1 vs. 0) | 1.09 | 0.54–2.19 | 0.816 | |||
| LDH (Elevated vs. Normal) | 1.73 | 1.06–2.82 | 0.029 | 1.44 | 0.80–2.58 | 0.225 |
| NLR (≥3 vs. < 3) | 1.19 | 0.72–1.96 | 0.500 | |||
| PD–L1 (1–49 vs. < 1%) | 0.59 | 0.24–1.43 | 0.240 | |||
| PD–L1 (≥50 vs. < 1%) | 0.65 | 0.30–1.42 | 0.281 | |||
| Brain metastases (Presence vs. Absence) | 2.10 | 1.00–4.43 | 0.049 | 1.66 | 0.66–4.20 | 0.283 |
| Liver metastases (Presence vs. Absence) | 1.14 | 0.63–2.05 | 0.660 | |||
| Bone metastases (Presence vs. Absence) | 1.74 | 1.08–2.8 | 0.023 | 1.79 | 1.07–3.00 | 0.026 |
Abbreviations: CRP C–reactive protein, NLR neutrophil to lymphocyte ratio, LDH lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, HR Hazard Ratio, CI Confidence Interval, ICI immune checkpoint inhibitor, n, number of patients
Bold values indicate p < 0.05, signifying statistical significance